Inventaire - your friends and communities are your best library

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

автор

Gerasimos Aravantinos

H P Kalofonos

George P Patrinos

Christos Christodoulou

опубликовано в: Cancer Chemotherapy and Pharmacology

дата публикации: 2015-02-17

главная тема: колоректальный рак, Бевацизумаб, colorectal carcinoma

Cites articles 42

Дата

Заголовок

Авторы

2015-01-01

Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
2014-03-01

Mechanistic considerations for the use of monoclonal antibodies for cancer therapy

Patrick M Glassman
2014-03-17

Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing
2013-11-20

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

Mats O Karlsson
2013-08-01

Role of bevacizumab in colorectal cancer growth and its adverse effects: a review
2013-06-26

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Andrew C. Hooker, Mats O Karlsson
2013-02-21

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts

Paolo Magni
2013-02-01

Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies
2012-09-26

Basic concepts in population modeling, simulation, and model-based drug development

Richard N Upton
2012-04-23

High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection
2012-05-01

The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
2012-06-01

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
2011-03-15

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

Fotios Loupakis, Chiara Cremolini, Lisa Salvatore, Teresa Di Desidero, Marta Schirripa, Antonello Di Paolo, Romano Danesi, Alfredo Falcone
2011-02-08

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models

Martin Bergstrand, Andrew C. Hooker
2011-12-01

Theoretical considerations of target-mediated drug disposition models: simplifications and approximations
2011-08-01

Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients

Soichiro Ishihara
2010-11-30

Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model

Aleksander S. Popel, Feilim Mac Gabhann, Marianne O Stefanini
2010-08-05

Bevacizumab.

Jos Beijnen, Jan H M Schellens
2010-07-29

Target-mediated drug disposition model for drugs that bind to more than one target.
2010-10-01

An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics

Gilles Paintaud
2009-08-01

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions
2009-07-01

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
2009-01

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Daniel J. Sargent
2009-04-01

Optimizing outcomes with bevacizumab by better targeting patients and tumors
2008-01-01

Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer

Jae Yong Park
2008-10-01

Approximations of the target-mediated drug disposition model and identifiability of model parameters.
2008-01-19

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
2007-01-01

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development
2007-11-13

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
2007-09-12

Platelets Take Up the Monoclonal Antibody Bevacizumab,Platelets take up the monoclonal antibody bevacizumab
2005-10-01

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)
2005-09-01

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Статья - wd:Q35193385

Добро пожаловать в Inventaire

the library of your friends and communities

узнать больше